Scotiabank lowered the firm’s price target on Kura Oncology (KURA) to $18 from $22 and keeps a Sector Perform rating on the shares. The firm adjusted its price target on the stock following recent lackluster mNPM-1 revumenib results reported by Syndax (SNDX) as well as the announced deal terms with Kyowa Kirin (KYKOF), the analyst tells investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KURA:
- Kura Oncology price target lowered to $34 from $37 at Wedbush
- Kura selling off on loss of acquisition premium, says TD Cowen
- Kura deal with Kyowa detracts from takeout narrative, says Mizuho
- Kura Oncology price target lowered to $28 from $32 at Jefferies
- Kura Oncology price target raised to $37 from $32 at H.C. Wainwright